INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion
INmune Bio (NASDAQ: INMB) said it filed its CORDStrom™ platform patent application into the U.S. national phase with the USPTO after a favorable PCT written opinion. The claims cover composition-of-matter and methods for Ebstrocel (pobistrocel) for epidermolysis bullosa and related engineered MSC modalities, with potential protection into at least 2045 if granted.
How this was made
The 30-second read
Why it matters
The newest concrete development is the USPTO national-phase submission following a favorable PCT written opinion, which the company frames as validating novelty/inventiveness and strengthening multi-decade exclusivity (projected to at least 2045 if granted).
Market read
This is a biotech IP de-risking update that can support valuation optionality, but it is not a clinical/regulatory outcome and lacks claim-grant confirmation.
What to watch
Traders may discount the impact until the company discloses claim breadth, prosecution status, or any linkage to upcoming UK/EU MHRA/EMA and U.S. BLA timing.
Background
The article describes the PCT-to-U.S. national-phase step for INmune Bio’s CORDStrom™ platform patent family, including Ebstrocel (pobistrocel) for epidermolysis bullosa and related engineered MSC modalities.
Ticker impact
INmune Bio says it advanced its CORDStrom™ platform patent application into the U.S. national phase after a favorable PCT written opinion.
Modest positive bias; likely limited near-term price impact unless paired with clinical/regulatory milestones or clearer claim scope.
The filing is a concrete IP milestone, but the article provides no granted claims, no financial guidance, and no immediate regulatory/clinical catalyst.
Market effects
Reinforces the broader biotech cell-therapy narrative that platform-level IP can extend exclusivity and improve valuation durability.
Highlights continued focus on U.S. patent enforcement as a key driver of global cell-therapy commercialization strategy.
Signals intent to expand patent filings across major jurisdictions, supporting long-horizon protection for multinational commercialization.
Counterpoint
A favorable PCT written opinion and national-phase entry do not guarantee granted claims; scope could narrow during USPTO examination.
Key entities
- companyINmune Bio Inc.
NASDAQ-listed late-stage biotech advancing CORDStrom™ platform IP into the U.S. national phase after a favorable PCT written opinion.
- platformCORDStrom™
Pooled, allogeneic, umbilical cord-derived MSC platform; patent application covers compositions, methods, and engineered/disease-biological selection modalities.
- product_candidateEbstrocel (pobistrocel)
Lead CORDStrom™ product candidate for epidermolysis bullosa (EB) included in the patent family.
- regulatory_processUSPTO / PCT
USPTO national-phase entry is the next step after the international PCT phase; written opinion is used to assess patentability prospects.
